JAMA Network Home
Sign In
Research Letter

Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer

JAMA Oncology 10.1001/jamaoncol.2025.4566

November 13, 2025 at 11:00 AM EST

Read the full article

This retrospective cohort study examines the association of upfront treatment with enfortumab vedotin plus pembrolizumab with clinical outcomes for patients with advanced urothelial cancer.

Corresponding Author: Ryan D. Chow, MD, PhD, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Perelman Center, 10th Floor, South Pavilion Extension, Philadelphia, PA 19104 (chowr@pennmedicine.upenn.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.4566?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111325

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks